FE 999326

Ferring Pharmaceuticals · Phase 3 active Small molecule Quality 0/100

At a glance

Generic name	FE 999326
Also known as	nadofaragene firadenovec
Sponsor	Ferring Pharmaceuticals
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FE 999326 CI brief — competitive landscape report
FE 999326 updates RSS · CI watch RSS
Ferring Pharmaceuticals portfolio CI